Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16334) 16334
Publication (1248) 1248
Book Review (402) 402
Book Chapter (238) 238
Dissertation (65) 65
Magazine Article (48) 48
Conference Proceeding (36) 36
Book / eBook (9) 9
Government Document (9) 9
Newspaper Article (6) 6
Data Set (2) 2
Presentation (2) 2
Web Resource (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bisphosphonates (10062) 10062
humans (7877) 7877
index medicus (6203) 6203
female (5174) 5174
osteoporosis (5174) 5174
bisphosphonate (4027) 4027
male (3636) 3636
zoledronic acid (2879) 2879
middle aged (2812) 2812
diphosphonates - therapeutic use (2799) 2799
aged (2782) 2782
animals (2727) 2727
alendronate (2388) 2388
endocrinology & metabolism (2350) 2350
bone density conservation agents - therapeutic use (2176) 2176
oncology (1784) 1784
fractures (1768) 1768
bone (1719) 1719
orthopedics (1683) 1683
diphosphonates - adverse effects (1658) 1658
diphosphonates - administration & dosage (1550) 1550
bones (1536) 1536
diphosphonates - pharmacology (1489) 1489
medicine & public health (1482) 1482
bone density conservation agents - adverse effects (1452) 1452
osteonecrosis (1425) 1425
postmenopausal women (1404) 1404
therapy (1395) 1395
osteoporosis - drug therapy (1368) 1368
risk factors (1362) 1362
cancer (1333) 1333
pamidronate (1325) 1325
adult (1303) 1303
in-vitro (1260) 1260
phosphonates (1257) 1257
aged, 80 and over (1256) 1256
pharmacology & pharmacy (1251) 1251
dentistry, oral surgery & medicine (1246) 1246
bone density conservation agents - administration & dosage (1219) 1219
dentistry (1198) 1198
bone density - drug effects (1188) 1188
care and treatment (1185) 1185
analysis (1177) 1177
rats (1157) 1157
diphosphonates (1117) 1117
treatment outcome (1107) 1107
drug therapy (1097) 1097
rheumatology (1097) 1097
women (1085) 1085
prevention (1061) 1061
surgery (1052) 1052
bone neoplasms - secondary (1016) 1016
mice (1007) 1007
postmenopausal osteoporosis (999) 999
research (996) 996
bone density (981) 981
bone mineral density (965) 965
bone-mineral density (918) 918
denosumab (912) 912
bone metastases (905) 905
risk (890) 890
health aspects (887) 887
breast cancer (885) 885
double-blind (819) 819
bone density conservation agents - pharmacology (803) 803
breast-cancer (803) 803
necrosis (803) 803
osteoporosis, postmenopausal - drug therapy (799) 799
endocrinology (785) 785
risedronate (767) 767
bone neoplasms - drug therapy (763) 763
apoptosis (748) 748
metastasis (740) 740
density (728) 728
medicine, general & internal (724) 724
jaw (719) 719
retrospective studies (710) 710
risk-factors (684) 684
bone resorption (670) 670
fracture (653) 653
imidazoles - therapeutic use (646) 646
nitrogen-containing bisphosphonates (632) 632
time factors (627) 627
calcium (623) 623
disease (614) 614
article (599) 599
management (591) 591
multiple-myeloma (577) 577
vitamin d (569) 569
cells (565) 565
dose-response relationship, drug (561) 561
imidazoles - pharmacology (550) 550
medicine, research & experimental (550) 550
osteoclasts (549) 549
patients (543) 543
resorption (535) 535
pain (533) 533
administration, oral (529) 529
internal medicine (527) 527
medicine (526) 526
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15204) 15204
German (420) 420
French (322) 322
Spanish (209) 209
Japanese (138) 138
Korean (65) 65
Portuguese (59) 59
Czech (54) 54
Russian (51) 51
Polish (47) 47
Chinese (42) 42
Italian (21) 21
Hungarian (18) 18
Turkish (16) 16
Slovenian (6) 6
Croatian (5) 5
Slovak (4) 4
Norwegian (3) 3
Arabic (2) 2
Belarusian (1) 1
Bosnian (1) 1
Dutch (1) 1
Estonian (1) 1
Lithuanian (1) 1
Persian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text MRONJ unrelated to bisphosphonates and denosumab
by Wadia, Reena
British Dental Journal, ISSN 0007-0610, 05/2019, Volume 226, Issue 10, pp. 794 - 794
Bisphosphonates
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Jaw Lesion and Discomfort
by Levin, Liran and Luder, Liat
JAMA: Journal of the American Medical Association, ISSN 0098-7484, 11/2013, Volume 310, Issue 20, pp. 2195 - 2195
Levin and Luder talk about intravenous bisphosphonates, which are primarily used for and are effective in the treatment and management of cancer-related... 
Bisphosphonates
Journal Article
Details down arrow
3. Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis
by Ford, John A and Jones, Rob and Elders, Andrew and Mulatero, Clive and Royle, Pamela and Sharma, Pawana and Stewart, Fiona and Todd, Radha and Mowatt, Graham
European Journal of Cancer, ISSN 0959-8049, 01/2013, Volume 49, Issue 2, pp. 416 - 430
Aim To evaluate the evidence for denosumab for the treatment of bone metastases secondary to solid tumours and, using a network meta-analysis, indirectly... 
Bisphosphonates
Journal Article
Details down arrow
4. PERIODONTAL DISEASE AND BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW
by Pihlstrom, Bruce Lee
Journal of the American Dental Association, ISSN 0002-8177, 11/2013, Volume 144, Issue 11, pp. 1294 - 1294
An abstract of a study by Hodges et al evaluating the association between radiographic evidence of periodontal disease and bisphosphonate-related osteonecrosis... 
Bisphosphonates
Journal Article
Details down arrow
5. Full Text Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology
by Fusco, Vittorio and Santini, Daniele and Armento, Grazia and Tonini, Giuseppe and Campisi, Giuseppina
Expert Opinion on Drug Safety, ISSN 1474-0338, 07/2016, Volume 15, Issue 7, pp. 925 - 935
Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of... 
sunitinib | Bisphosphonate | everolimus | temsirolimus | aflibercept | Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) | bevacizumab | Osteonecrosis of the jaw (ONJ) | Medication-Related Osteonecrosis of the Jaw (MRONJ) | denosumab | RISK-FACTORS | AMERICAN ASSOCIATION | RENAL-CELL CARCINOMA | TYROSINE KINASE INHIBITORS | ZOLEDRONIC ACID | BREAST-CANCER | CANCER-PATIENTS | BISPHOSPHONATE-RELATED OSTEONECROSIS | SURGEONS POSITION PAPER | PHARMACOLOGY & PHARMACY | Jaw Diseases - diagnosis | Osteonecrosis - diagnosis | Risk Assessment - methods | Humans | Antineoplastic Agents - administration & dosage | Osteonecrosis - pathology | Molecular Targeted Therapy | Neoplasms - drug therapy | Jaw Diseases - chemically induced | Angiogenesis Inhibitors - administration & dosage | Jaw Diseases - pathology | Antineoplastic Agents - adverse effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Quality of Life | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Osteonecrosis - chemically induced | Angiogenesis Inhibitors - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates – preliminary data
by Anon
British Dental Journal, ISSN 0007-0610, 04/2013, Volume 214, Issue 7, pp. 349 - 349
  Ozone offers 'a promising...therapeutic option'. 
Bisphosphonates
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Farnesyl pyrophosphate synthase: a key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development
by Dhar, Manoj K and Koul, Archana and Kaul, Sanjana
New Biotechnology, ISSN 1871-6784, 01/2013, Volume 30, Issue 2, pp. 114 - 123
As isoprenoid biosynthetic pathway has gained importance since last few years, key enzymes of this pathway have been characterized and their functional roles... 
Bisphosphonates
Journal Article
Details down arrow
8. Full Text Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015
by Khan, A and Morrison, A and Cheung, A and Hashem, W and Compston, J
Osteoporosis International, ISSN 0937-941X, 3/2016, Volume 27, Issue 3, pp. 853 - 859
Osteonecrosis of the jaw (ONJ) has been associated with the use of aminobisphosphonates and denosumab. The vast majority (>90 %) of cases occur in the oncology... 
Treatment | Medicine & Public Health | Orthopedics | Rheumatology | Osteonecrosis | Diagnosis | Denosumab | Bisphosphonates | Endocrinology | BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | ORAL BISPHOSPHONATES | TERIPARATIDE THERAPY | INTRAVENOUS BISPHOSPHONATES | ZOLEDRONIC ACID | MAXILLOFACIAL SURGEONS | POSTMENOPAUSAL OSTEOPOROSIS | REDUCED INCIDENCE | ENDOCRINOLOGY & METABOLISM | BREAST-CANCER PATIENTS | OF-THE-LITERATURE | Severity of Illness Index | Humans | Risk Factors | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Biomedical Research - trends | Disease Management | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Care and treatment | Diphosphonates | Analysis | Bones | Health aspects | Necrosis | Case studies | Gangrene | Medical diagnosis | Mouth | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Issues with the surgical treatment of antiresorptive agent‐related osteonecrosis of the jaws
by Kagami, H and Inoue, M and Kobayashi, A and Taguchi, A and Li, X and Yoshizawa, M
Oral Diseases, ISSN 1354-523X, 03/2018, Volume 24, Issue 1-2, pp. 52 - 56
Antiresorptive agent‐related osteonecrosis of the jaw is a rare but significant complication in patients using antiresorptive agents such as bisphosphonates... 
bisphosphonate | osteonecrosis | surgical management | antiresorptives | bisphosphonate‐related osteonecrosis of the jaws | osteonecrosis of the jaws | bisphosphonate-related osteonecrosis of the jaws | MANAGEMENT | MRONJ | CANCER-PATIENTS | MEDICATION-RELATED OSTEONECROSIS | DENTISTRY, ORAL SURGERY & MEDICINE | BISPHOSPHONATE-RELATED OSTEONECROSIS | CASE SERIES | OUTCOMES | Piezosurgery | Severity of Illness Index | Bone Density Conservation Agents - adverse effects | Humans | Laser Therapy | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Conservative Treatment | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Denosumab - adverse effects | Diphosphonates - adverse effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - surgery | Bones | Care and treatment | Surgery | Necrosis | Jaw | Clinical aspects | Osteonecrosis | Bisphosphonates | Maxillofacial surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
by Ruggiero, Salvatore L., DMD, MD and Dodson, Thomas B., DMD, MPH and Fantasia, John, DDS and Goodday, Reginald, DDS, MSc and Aghaloo, Tara, DDS, MD, PhD and Mehrotra, Bhoomi, MD and O'Ryan, Felice, DDS and American Association of Oral and Maxillofacial Surgeons
Journal of Oral and Maxillofacial Surgery, ISSN 0278-2391, 2014, Volume 72, Issue 10, pp. 1938 - 1956
Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of... 
Surgery | ZOLEDRONIC ACID | BREAST-CANCER | JAW-LIKE DISEASE | RISK-FACTORS | MULTIPLE-MYELOMA PATIENTS | DENTISTRY, ORAL SURGERY & MEDICINE | BISPHOSPHONATE-RELATED OSTEONECROSIS | TOOTH EXTRACTION | RENAL-CELL CARCINOMA | LONG-TERM EFFICACY | CROSS-LINKING TELOPEPTIDE | Jaw Diseases - diagnosis | Neovascularization, Physiologic - drug effects | Humans | Jaw Diseases - therapy | Osteoporosis - drug therapy | Bone Remodeling - drug effects | Oral Surgical Procedures - adverse effects | Jaw Diseases - chemically induced | Patient Care Planning | Time Factors | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - adverse effects | Osteonecrosis - diagnosis | Diagnosis, Differential | Osteonecrosis - therapy | Bone Density Conservation Agents - adverse effects | Risk Assessment | Risk Factors | Terminology as Topic | Neoplasms - drug therapy | Bone Resorption - prevention & control | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Osteonecrosis - chemically induced | Medical colleges | Strategic planning (Business) | Surgeons | Bones | College teachers | Trade and professional associations | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Osseointegration of Dental Implants and Osteonecrosis of the Jaw in Patients Treated With Bisphosphonate Therapy: A Systematic Review
by Chadha, Gurpreet K and Ahmadieh, Azadeh and Kumar, Satish and Sedghizadeh, Parish P
Journal of Oral Implantology, ISSN 0160-6972, 01/2013, Volume 39, Issue 4, pp. 510 - 510
Bisphosphonate (BP) drugs are a commonly prescribed group of medications used in the treatment of metabolic and oncologic bone disorders. The aim of this study... 
Bisphosphonates
Journal Article
Details down arrow
12. Role of brain macrophages on IL-1b and fatigue following eccentric exercise-induced muscle damage
by Carmichael, Martin D and Davis, JMark and Murphy, EAngela and Carson, James A and Van Rooijen, N and Mayer, Eugene and Ghaffar, Abdul
Brain, Behavior, and Immunity, ISSN 0889-1591, 05/2010, Volume 24, Issue 4, pp. 564 - 568
Fatigue associated with recovery from muscle damage has recently been linked to increases in brain and muscle proinflammatory cytokines. However, little is... 
Bisphosphonates
Journal Article
Details down arrow
13. Full Text Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease
by Bedogni, Alberto and Fedele, Stefano and Bedogni, Giorgio and Scoletta, Matteo and Favia, Gianfranco and Colella, Giuseppe and Agrillo, Alessandro and Bettini, Giordana and Di Fede, Olga and Oteri, Giacomo and Fusco, Vittorio and Gabriele, Mario and Ottolenghi, Livia and Valsecchi, Stefano and Porter, Stephen and Petruzzi, Massimo and Arduino, Paolo and D’Amato, Salvatore and Ungari, Claudio and Fung Polly, Pok-Lam and Saia, Giorgia and Campisi, Giuseppina
British Journal of Oral and Maxillofacial Surgery, ISSN 0266-4356, 2014, Volume 52, Issue 7, pp. 603 - 608
Abstract Management of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease... 
Surgery | Antiresorptive agents | Bisphosphonate | Staging system | Computed tomography | Osteonecrosis of the jaw | AAOMS | SYSTEM | SURGERY | MANAGEMENT | SERIES | IMAGING FINDINGS | VARIANT | CANCER | DENTISTRY, ORAL SURGERY & MEDICINE | BISPHOSPHONATE-RELATED OSTEONECROSIS | SURGICAL RESECTION | Dental Fistula - diagnostic imaging | Humans | Middle Aged | Tomography, Spiral Computed - methods | Tomography, X-Ray Computed - methods | Male | Dental Fistula - classification | Suppuration | Bisphosphonate-Associated Osteonecrosis of the Jaw - classification | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnostic imaging | Cutaneous Fistula - diagnostic imaging | Tooth Extraction | Aged, 80 and over | Adult | Female | Retrospective Studies | Drug Therapy, Combination | Mandibular Diseases - classification | Osteosclerosis - diagnostic imaging | Bone Density Conservation Agents - adverse effects | Mandibular Fractures - diagnostic imaging | Osteosclerosis - classification | Maxillary Diseases - classification | Maxillary Diseases - diagnostic imaging | Patient Acuity | Mandibular Diseases - diagnostic imaging | Phenotype | Alveolar Process - diagnostic imaging | Aged | Cutaneous Fistula - classification | Mandibular Fractures - classification | Cone-Beam Computed Tomography - methods | CT imaging | Bones | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Biochemical and molecular mechanisms of action of bisphosphonates
by Rogers, Michael J and Crockett, Julie C and Coxon, Fraser P and Mönkkönen, Jukka
Bone, ISSN 8756-3282, 2010, Volume 49, Issue 1, pp. 34 - 41
Abstract This review describes the key discoveries over the last 15 years that have led to a clearer understanding of the molecular mechanisms by which... 
Orthopedics | Prenylation | GGPP | ApppI | Mevalonate | FPP | IPP | GTPase | Cholesterol | OSTEOCLASTS IN-VITRO | NITROGEN-CONTAINING BISPHOSPHONATES | PYROPHOSPHATE SYNTHASE | GTP-BINDING PROTEINS | HETEROCYCLE-CONTAINING BISPHOSPHONATES | FARNESYL DIPHOSPHATE SYNTHASE | RAB GERANYLGERANYL TRANSFERASE | ENDOCRINOLOGY & METABOLISM | INHIBITS BONE-RESORPTION | MEVALONATE PATHWAY | MOLD DICTYOSTELIUM-DISCOIDEUM | Protein Prenylation - drug effects | Animals | Intracellular Space - drug effects | Diphosphonates - chemistry | Humans | Intracellular Space - metabolism | Dimethylallyltranstransferase - metabolism | Dimethylallyltranstransferase - antagonists & inhibitors | Metabolic Networks and Pathways - drug effects | Diphosphonates - pharmacology | Bone and Bones - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer
by Schiodt, Morten and Vadhan-Raj, Saroj and Chambers, Mark S and Nicolatou-Galitis, Ourania and Politis, Constantinus and Coropciuc, Ruxandra and Fedele, Stefano and Jandial, Danielle and Zhang, Jeffrey and Ma, Haijun and Saunders, Deborah P
Supportive Care in Cancer, ISSN 0941-4355, 6/2018, Volume 26, Issue 6, pp. 1905 - 1915
This observational case registry study was designed to describe the natural history of cancer patients with medication-related osteonecrosis of the jaw (ONJ)... 
Pain Medicine | Nursing | Rehabilitation Medicine | Treatment | Medicine & Public Health | Nursing Research | Osteonecrosis of the jaw | Oncology | Denosumab | Bisphosphonates | Risk factors | Outcomes | BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | RISK-FACTORS | DENTAL IMPLANTS | BONE METASTASES | PREVENTION | ZOLEDRONIC ACID | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | CASE SERIES | POSITION PAPER | TOOTH EXTRACTION | Humans | Middle Aged | Risk Factors | Bone Density Conservation Agents - therapeutic use | Bisphosphonate-Associated Osteonecrosis of the Jaw - epidemiology | Male | Disease Progression | Denosumab - therapeutic use | Neoplasms - complications | Neoplasms - therapy | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Diphosphonates - therapeutic use | Adult | Female | Registries | Aged | Neoplasms - pathology | Bisphosphonate-Associated Osteonecrosis of the Jaw - complications | Neoplasms - epidemiology | Palliative care | Bone diseases | Face | Cancer | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
by Saad, F and Brown, J.E and Van Poznak, C and Ibrahim, T and Stemmer, S.M and Stopeck, A.T and Diel, I.J and Takahashi, S and Shore, N and Henry, D.H and Barrios, C.H and Facon, T and Senecal, F and Fizazi, K and Zhou, L and Daniels, A and Carrière, P and Dansey, R
Annals of Oncology, ISSN 0923-7534, 05/2012, Volume 23, Issue 5, pp. 1341 - 1347
Osteonecrosis of the jaw (ONJ) has been reported in patients receiving bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes... 
Zoledronic acid | Denosumab | Osteonecrosis of the jaw | Bone metastases | NECROSIS | osteonecrosis of the jaw | ONCOLOGY | MULTIPLE-MYELOMA PATIENTS | zoledronic acid | BISPHOSPHONATE-RELATED OSTEONECROSIS | bone metastases | IMPLEMENTATION | EXPERIENCE | ONJ | denosumab | PREVENTIVE MEASURES | Prognosis | Humans | Middle Aged | Bone Neoplasms - secondary | Bone Neoplasms - epidemiology | Male | Neoplasms - diagnosis | Incidence | Clinical Trials, Phase III as Topic - statistics & numerical data | Diphosphonates - therapeutic use | Female | Imidazoles - therapeutic use | Diphosphonates - adverse effects | Data Interpretation, Statistical | Randomized Controlled Trials as Topic - statistics & numerical data | Bone Neoplasms - diagnosis | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Imidazoles - adverse effects | Risk Factors | Bone Density Conservation Agents - therapeutic use | Bisphosphonate-Associated Osteonecrosis of the Jaw - epidemiology | Neoplasms - drug therapy | Algorithms | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Neoplasms - pathology | Neoplasms - epidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. The Role of the Innated Immune System in Bisphonate-induced Osteonecrosis of the Jaw
by Forster, Carol
11/2011
Bisphosphonate-induced osteonecrosis of the jaw (BPONJ) has been identified as a severe complication of dental treatment in 1-10% of patients previously... 
Bisphosphonate | 0410 | Neutrophil
Dissertation
Details down arrow